Register now
Register to receive full, unrestricted access to our resources, regular updates and partnership opportunities
This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.
This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.
Adverse events reporting information can be found in the footer of this page.
This episode focuses on collaborative working projects (CWPs) in cardiovascular disease (CVD), exploring how partnership approaches can support service transformation and improve outcomes for patients with complex cardiovascular needs.
Hosted by John Bingham from The Clarion Portfolio, the session features expert insights from Jeremy Dixon, Value & Access Marketing Director, and Helen Fotheringham, Solution & Service Design Lead, at Novartis UK. It also includes practical perspectives from key team members at Buckinghamshire Healthcare NHS Trust, shared through pre-recorded clips, discussing a current initiative focused on embedding a new approach to lipid management within local CVD pathways.
Together, they share real-world experience and key learnings from developing and implementing this collaborative project. The discussion highlights the opportunities CWPs present in transforming services, the considerations involved in delivering successful projects, and the impact of effective collaboration between industry and the NHS.
See how a collaborative approach is helping to identify opportunities to improve outcomes while enabling more coordinated and efficient care.
This episode is part of our series exploring the impact of collaborative working in the UK. Discover the other episodes in the series below and hear more about these innovative partnerships in action.
Discover how partnership-led change between the pharmaceutical industry and the NHS is shaping the future of healthcare.
UK | June 2026 | FA-11644720 Fictional patient and healthcare professional images.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.